GD2-targeted CAR-T cells / Sinobioway - LARVOL DELTA

GD2-targeted CAR T cell therapy for childhood solid tumours (EACR 2024) - No abstract available

CAR T-Cell Therapy • Clinical • Oncology • Solid Tumor

Priming of the glioblastoma tumour microenvironment via copper chelation to enhance the efficacy of immunotherapies (AACR 2024) - "In an immunocompetent murine glioblastoma model, combination therapy with GD2-targeted CAR-T cells and TETA effectively slowed tumor growth, demonstrating enhanced efficacy...Our findings suggest that copper chelation, with agents like TETA, can be repurposed as a viable anticancer therapy when combined with immunotherapies. This study provides a compelling rationale for further pre-clinical validation, offering a potential breakthrough in the quest for effective glioblastoma treatments."

Clinical • IO biomarker • Tumor microenvironment • Brain Cancer • CNS Tumor • Glioblastoma • Hematological Malignancies • Oncology • Solid Tumor • PD-L1

GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. (PubMed, N Engl J Med) - P1/2 | "The use of GD2-CART01 was feasible and safe in treating high-risk neuroblastoma. Treatment-related toxic effects developed, and the activation of the suicide gene controlled side effects. GD2-CART01 may have a sustained antitumor effect. (Funded by the Italian Medicines Agency and others; ClinicalTrials.gov number, NCT03373097.)."

Journal • CNS Tumor • Neuroblastoma • Neuroendocrine Tumor • Oncology • Solid Tumor

AUTO6NG: Next generation GD2-targeting CAR T-cell therapy with improved persistence and insensitivity to TGFβ and checkpoint inhibition for relapsed/refractory neuroblastoma (SITC 2019) - P1; "The AUTO6NG product consists of 3 distinct populations of GD2-targeted CAR T-cells, produced by dual transduction of T-cells with two separate retroviral vectors... These results demonstrate the feasibility, safety, and efficacy of AUTO6NG T-cells. The addition of IL7R_CCR, dnTGFβRII and dSHP2 modules to the AUTO6NG product augment its functions by extending T-cell persistence and rendering modified T-cells resistant to TGFβ- and PD1/PDL1-driven immune inhibition."

CAR T-Cell Therapy • Checkpoint inhibition • IO Biomarker • PD(L)-1 Biomarker

Chimeric Antigen Receptor 4SCAR-GD2-Modified T Cells Targeting High-Risk and Recurrent Neuroblastoma: A Phase II Multi-Center Trial in China (ASH 2017) - P2,P1/2; "Before CART infusion, patients received cyclophosphamide and fludarabine conditioning. This multicenter trial demonstrates that the 4SCAR-GD2 T cells are safe and effective for treating high-risk stage IV NB children. The correlations of GD2 expression in tumor, CART kinetics in blood and treatment responses could not be statistically established, suggesting a vast disease heterogeneity. Important therapeutic correlates require a large patient cohort and long-term follow-ups to elucidate."

Clinical • P2 data • Biosimilar • Dermatology • Hematological Malignancies • Immunology • Neuroendocrine Tumor • Pain

[VIRTUAL] AUTO6NG overcomes immune suppressive mechanisms in the TME and demonstrate preclinical anti-tumor activity in GD2-expressing solid tumors (AACR-II 2020) - "Immune-checkpoint blockade therapies has had impressive results in the clinic and are approved in multiple cancer indications. These CAR-T cells also demonstrated enhanced tumor infiltration and anti-tumor activity in vivo in xenografts mouse models. Our findings suggest that GD2 targeted CAR-T cell therapy is a viable novel approach for the treatment of multiple solid tumors indications."

IO Biomarker • Preclinical • Lung Cancer • Melanoma • Neuroblastoma • Oncology • Small Cell Lung Cancer • Thoracic Cancer

Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M diffuse midline gliomas. (PubMed, Nat Med) - "Given the precarious neuroanatomical location of midline gliomas, careful monitoring and aggressive neurointensive care management will be required for human translation. With a cautious multidisciplinary clinical approach, GD2-targeted CAR T cell therapy for H3-K27M diffuse gliomas of pons, thalamus and spinal cord could prove transformative for these lethal childhood cancers."

CAR T-Cell Therapy • Clinical • Journal